Interesting Images68Ga-DOTATATE and 18F-FDG in Castleman DiseaseVerçosa, Alinne Fernanda Amaral MD∗; Flamini, Maria Eduarda Duarte de Mello MSc∗,†; Loureiro, Luiz Victor Maia PhD‡; Flamini, Rodrigo de Carvalho MD∗Author Information From the ∗Nuclear Medicine Department, NOVA Diagnóstico por Imagem, João Pessoa †Nuclear Medicine Department, Hospital das Clínicas–Universidade Federal de Pernambuco, Recife ‡Internal Medicine Department, Universidade Federal da Paraíba–UFPE, João Pessoa, Brazil. Received for publication January 30, 2020; revision accepted July 28, 2020. Conflicts of interest and sources of funding: none declared. Correspondence to: Maria Eduarda Duarte de Mello Flamini, MSc, Rua José Aderval Chaves, 230/2501, Boa Viagem, 51111-030 Recife, Brazil. E-mail: [email protected]. Clinical Nuclear Medicine: November 2020 - Volume 45 - Issue 11 - p 868-870 doi: 10.1097/RLU.0000000000003277 Buy Metrics Abstract A 35-year-old woman with rectal neuroendocrine tumor, Ki-67 proliferation index less than 2%, and a mediastinal mass on CT postoperatively was referred for restaging with PET/CT 68Ga-DOTATATE. The examination showed uptake on the pelvic lymph node and mediastinal mass. Because of differences in lesions’ SUVs and clinical presentation, the hypothesis of lymphoma for the mediastinal mass was raised, and 18F-FDG PET/CT was performed, which showed glycolytic hypermetabolism in the mediastinal mass and absence of hypermetabolism in pelvic lymph nodes. Transthoracic biopsy of the mass revealed atypical large-cell lymphoid proliferation, and immunohistochemistry study was compatible with Castleman disease. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.